Published in AIDS Weekly, February 6th, 2006
In a recent report, researchers in Germany conducted a study to "analyze the evolution of resistance patterns in patients undergoing treatment interruption (TI) and reinitiating highly active antiretroviral therapy (HAART).
"HIV-RT and -PR gene-sequences were analyzed in 14 patients (>5 failing prior drugs) before and during TI and under a new HAART. Genotypes were interpreted using two bioinformatics systems. Additionally, virus load (VL) and CD4+-T-cell counts were measured."
"Six patients (42%) achieved sustained undetectable VL up to 1 year after TI...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.